TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1271-1280

  Amiset, Laurent ^a   Fend, Laetitia ^a   Gatard Scheikl, Tania ^a   Rittner, Karola ^a   Duong, Vanessa ^a   Rooke, Ronald ^a   Muller, Sylviane ^b   Bonnefoy, Jean Yves ^a   Préville, Xavier ^a   Haegel, Hélène ^a  

^a TRANSGENE S A   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cancer; Immunotherapy; Pam3Cys; Th17; TLR2; Treg

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; LIPOPEPTIDE PAM3CYSTEINE VACCINE; MODIFIED VACCINIA VIRUS ANKARA MUCIN 1 VACCINE; PROTEIN BCL XL; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFICACY; HELPER CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION;

EID: 84886945273     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21479     Document Type: Article

References (44)

1. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188:51-64; PMID:12445281; http://dx.doi.org/10.1034/j.1600-065X.2002.18806.x.
2. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008; 222:328-40; PMID:18364012; http://dx.doi.org/10.1111/j.1600-065X.2008.00611.x.
3. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60:319-26; PMID:21267721; http://dx.doi.org/10.1007/s00262-010-0968-0.
4. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010; 10:1573-86; PMID:20955112; http://dx.doi.org/10.1517/14712598.2010.529126.
5. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55:1064-71; PMID:16328385; http://dx.doi.org/10.1007/s00262-005-0092-8.
6. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res 2010; 46:79-93; PMID:19763889; http://dx.doi.org/10.1007/s12026-009-8124-7.
7. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx.doi.org/10.1016/j.immuni.2009.04.010.
8. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009; 21:281-5; PMID:19500966; http://dx.doi.org/10.1016/j.coi.2009.05.007.
9. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112:2340-52; PMID:18617638; http://dx.doi.org/10.1182/blood-2008-01-133967.
10. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol 2008; 38:3274-81; PMID:19039774; http://dx.doi.org/10.1002/eji.200838950.
11. Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX, Constantinescu CS, et al. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 2011; 187:2278-90; PMID:21775683; http://dx.doi.org/10.4049/jimmunol.1003715.
12. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8:967-74; PMID:17581537; http://dx.doi.org/10.1038/ni1488.
13. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006; 25:455-71; PMID:16973386; http://dx.doi.org/10.1016/j.immuni.2006.07.011.
14. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-61; PMID:17635957; http://dx.doi.org/10.1084/jem.20070663.
15. Acres B, Bonnefoy JY. Clinical development of MVAbased therapeutic cancer vaccines. Expert Rev Vaccines 2008; 7:889-93; PMID:18767940; http://dx.doi.org/10.1586/14760584.7.7.889.
16. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004; 38:1749-53; PMID:15227622; http://dx.doi.org/10.1086/421266.
17. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007; 6:481-6; PMID:18027437; http://dx.doi.org/10.4161/cbt.6.4.4201.
18. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009; 5:e1000480; PMID:19543380; http://dx.doi.org/10.1371/journal.ppat.1000480.
19. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309:1380-4; PMID:16123302; http://dx.doi.org/10.1126/science.1113401.
20. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007; 13:6947-58; PMID:18056169; http://dx.doi.org/10.1158/1078-0432.CCR-07-0842.
21. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130:1071-82; PMID:17889651; http://dx.doi.org/10.1016/j.cell.2007.09.008.
22. Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116:485-94; PMID:16424940; http://dx.doi.org/10.1172/JCI25439.
23. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006; 103:7048-53; PMID:16632602; http://dx.doi.org/10.1073/pnas.0601554103.
24. Chen Q, Davidson TS, Huter EN, Shevach EM. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J Immunol 2009; 183:4458-66; PMID:19748987; http://dx.doi.org/10.4049/jimmunol.0901465.
25. Oberg HH, Ly TT, Ussat S, Meyer T, Kabelitz D, Wesch D. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J Immunol 2010; 184:4733-40; PMID:20363971; http://dx.doi.org/10.4049/jimmunol.0804279.
26. Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, et al. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol 2011; 186:1963-9; PMID:21217015; http://dx.doi.org/10.4049/jimmunol.1002320.
27. Cottalorda A, Verschelde C, Marçais A, Tomkowiak M, Musette P, Uematsu S, et al. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 2006; 36:1684-93; PMID:16761317; http://dx.doi.org/10.1002/eji.200636181.
28. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 2004; 101:3029-34; PMID:14981245; http://dx.doi.org/10.1073/pnas.0400171101.
29. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Tolllike receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008; 22:3628-37; PMID:18587008; http://dx.doi.org/10.1096/fj.08-108274.
30. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007; 19:39-45; PMID:17129718; http://dx.doi.org/10.1016/j.coi.2006.11.007.
31. Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J 2010; 16:342-7; PMID:20693845; http://dx.doi.org/10.1097/PPO.0b013e3181eb336d.
32. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947.
33. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106; PMID:19769742; http://dx.doi.org/10.1111/j.1749-6632.2009.04939.x.
34. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183:3170-6; PMID:19648274; http://dx.doi.org/10.4049/jimmunol.0803721.
35. Pillemer BB, Qi Z, Melgert B, Oriss TB, Ray P, Ray A. STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells. J Immunol 2009; 183:155-63; PMID:19535633; http://dx.doi.org/10.4049/jimmunol.0803733.
36. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734.
37. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID:16648838; http://dx.doi.org/10.1038/nature04753.
38. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121-33; PMID:16990136; http://dx.doi.org/10.1016/j.cell.2006.07.035.
39. Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011; 186:4388-95; PMID:21357259; http://dx.doi.org/10.4049/jimmunol.1003251.
40. Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010; 185:4063-71; PMID:20805420; http://dx.doi.org/10.4049/jimmunol.0902609.
41. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112:362-73; PMID:18354038; http://dx.doi.org/10.1182/blood-2007-11-120998.
42. Reynolds JM, Pappu BP, Peng J, Martinez GJ, Zhang Y, Chung Y, et al. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 2010; 32:692-702; PMID:20434372; http://dx.doi.org/10.1016/j.immuni.2010.04.010.
43. Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, et al. Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem 1990; 189:463-73; PMID:2351132; http://dx.doi.org/10.1111/j.1432-1033.1990.tb15511.x.
44. Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou j. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996; 65:664-70; PMID:8598319; http://dx.doi.org/10.1002/(SICI)1097-0215(19960301)65:5<664::AID-IJC17>3.0.CO;2-7.